BIA builds on continued strength with new Board and staff appointments

The new and re-elected Board members will serve from 1 January for a term of three years

The UK's BioIndustry Association (BIA) has appointed Mark Bodmer, Vice President, Head of Immunology, UCB; Charles Brigden, Senior Vice President and Head of Business Development, BTG; Celia Caulcott, Executive Director, Innovation and Skills, BBSRC; and Keith Thompson, Chief Executive, Cell Therapy Catapult to its Board of Directors.

In addition, Sam Williams, Chief Executive of Modern Biosciences, has been re-appointed to the Board.

The new and re-elected Board members will serve from 1 January 2015 for a term of three years.

Alongside these appointments, the BIA has also welcomed new Director of Public Affairs and Communications, Pamela Learmonth, and Chief Operating Officer, Nick Gardiner, to the team.

​Steve Bates, BIA Chief Executive, commented: 'It’s been a great year for UK biotech, accompanied by a number of significant successes for the BIA in areas such as access to medicines, the recent expanded Research and Bolar Exemptions and being a leading partner in the formal establishment of the Medicines Manufacturing Industry Partnership (MMIP). These new appointments will enable the BIA to continue its work, supporting the UK as the leader in European biotech.'

You may also like

Research & Development

The power of national collaboration

To expedite the scale-up and production of a COVID-19 vaccine, the UK BioIndustry Association issued a call to arms to its members, reports Steve Bates, CEO
Regulatory

Waiting in the shadow of a no deal Brexit

Pharmaceutical companies still do not know how they will be impacted by Brexit after Prime Minister Theresa May decided to postpone a vote on her deal with the European Union (EU), writes Paul Brooks, Executive Director, RAPS
Media

Life Sciences sector responds to report on the impact of Brexit

The Business, Energy and Indsutrial Strategy (BEIS) Committee report calls on the Government to secure a post-Brexit deal to protect patients and the UK's pharmaceutical industry
Regulatory

Life Sciences Industrial Strategy paves way to support UK bioscience growth

The BioIndustry Association (BIA) welcomes the publication of the Life Sciences Industrial Strategy
Media

BIA report shows UK is on track to build the world’s third global biotech cluster

CEO Steve Bates attributes this to an “entrepreneurial and resilient community that is staffed by great management teams”
Media

Triggering Article 50

On 29th March, the UK government triggered Article 50 which officially marks the start of the UK’s exit from the European Union. Home to a world-leading life science industry, the countdown of Britain leaving the EU has inevitably created a stir within the UK’s pharmaceutical industry
Regulatory

BIA explore options for working with EU post-Brexit

The UK BioIndustry Association will send a delegation to Switzerland, to learn from their outside-of-EU system
Subscribe now